Merck & Co. is +83% over the past year while the S&P 500 is +18%: 64 points ahead of the market. 1-year return: +83% (S&P 500 +18%). vs 200-day average: +20%, a clear uptrend. RSI (14): 41, neutral. Below its 52-week high: 7.0%.

MRKMerck & Co.

Healthcare

$145.57+83% 1Y

$145.57

$75.8352 weeks$156.44

What is the market doing?

Mixed

No clear lean: nothing decisive, though in an uptrend.

1 good, 2 neutral

TrendUptrendderived · Oct 9, 2026

In an uptrend, above its rising 50- and 200-day averages. Price is +20% vs its 200-day average.

Insider conviction−$30.0M (90 days to Oct 9, 2026)SEC EDGAR · Oct 9, 2026

Insiders were net sellers over the 90 days ending Oct 9, 2026; selling is often routine (taxes, diversification).

Short interest1.1% of sharesFINRA · Sep 30, 2026

Lightly shorted, settled Sep 30, 2026, a few days of normal trading to cover. Down 18% since the previous count, down from 1.3% of shares outstanding three months ago.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

1-year returntop 10% of the market

vs 200-day avgbetter than 85% of the market

Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.

How MRK is trading

Merck & Co. is +83% over the past year while the S&P 500 is +18%: 64 points ahead of the market.

+83%

1-year return · S&P 500 +18%

vs 200-day average: +20%
vs 200-day average · a clear uptrend
RSI (14): 41
RSI (14) · neutral
Below its 52-week high: 7.0%
Below its 52-week high

Sep 17, 2024$70.39 – $156.44 · dashed line: 200-day averageOct 9, 2026

Details›

Last close2026-10-09: $145.57
1 monthS&P 500 +2.7%: +0.60%
1 yearS&P 500 +18%: +83%
5 yearsS&P 500 +88%: +132%
vs 50-day average$143.16: +1.7%
52-week high: $156.44
52-week low: $75.83
Annualised volatility: 29%
Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-09: −$30M

Calendar-year price return
Year	Return
2026 (year to date)	+40%
2025	+9.8%
2024	−6.3%
2023	+1.0%
2022	+49%
2021	+1.8%
2020	−7.2%
2019	+22%
2018	+40%
2017	−1.5%

Average return by calendar month, 2016–2026
Month	Years	Positive	Average
Jan	10	5 of 10	+1.4%
Feb	10	4 of 10	−0.54%
Mar	10	7 of 10	+1.9%
Apr	10	4 of 10	+0.08%
May	10	7 of 10	+0.53%
Jun	10	6 of 10	+2.4%
Jul	11	4 of 11	+0.13%
Aug	11	8 of 11	+3.9%
Sep	11	5 of 11	−0.63%
Oct	11	6 of 11	+0.42%
Nov	10	7 of 10	+3.5%
Dec	10	7 of 10	+1.6%

End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.

On our screens:Quality at a reasonable price Stocks that buy back more than they dilute

Drug Manufacturers, General

The closest names by size in the same industry